Objective To confirm in a placebo‐controlled trial the safety and efficacy profile of infliximab
in short‐term treatment of patients with active spondylarthropathy (SpA). Methods Forty …

… F De Keyser1 … This work was supported by a grant from the ‘Vlaams instituut voor de
bevordering van het wetenschappelijk-technologisch onderzoek in de industrie’ (IWT/SB/11127) …

Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of the skin and
internal organs that leads to profound disability and premature death. To identify new SSc …

Background Plasmacytoid dendritic cells have been implicated in the pathogenesis of
systemic sclerosis through mechanisms beyond the previously suggested production of type I …

OBJECTIVES To compare the macroscopic and microscopic characteristics of synovial
tissue in rheumatoid arthritis (RA), spondyloarthropathy (SpA), and osteoarthritis (OA) after …

Objective To determine the overall prevalence of spondyloarthropathy (SpA) among patients
with inflammatory bowel disease (IBD)[Crohn's disease (CD) and ulcerative colitis (UC)]. …

At present only few biological data are available to indicate whether psoriatic arthritis (PsA)
is part of the spondyloarthropathy (SpA) concept, whether it is a separate disease entity or a …

The Sm proteins B/B′, D1, D2, D3, E, F, and G are components of the small nuclear
ribonucleoproteins U1, U2, U4/U6, and U5 that are essential for the splicing of pre-mRNAs in …

OBJECTIVE To evaluate the efficacy and safety of a loading dose regimen of three
intravenous infusions with infliximab in patients with active spondyloarthropathy. METHODS A …

Four patients with Crohn's disease and spondyloarthropathy were treated with infliximab for
treatment-resistant gut inflammation. A substantial improvement in gastrointestinal signs and …